TY - JOUR
T1 - Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics
AU - Becquemont, Laurent
AU - Alfirevic, Ana
AU - Amstutz, Ursula
AU - Brauch, Hiltrud
AU - Jacqz-Aigrain, Evelyne
AU - Laurent-Puig, Pierre
AU - Molina, Miguel A.
AU - Niemi, Mikko
AU - Schwab, Matthias
AU - Somogyi, Andrew A.
AU - Thervet, Eric
AU - Maitland-van der Zee, Anke-Hilse
AU - van Kuilenburg, André B. P.
AU - van Schaik, Ron H. N.
AU - Verstuyft, Céline
AU - Wadelius, Mia
AU - Daly, Ann K.
PY - 2011
Y1 - 2011
N2 - The present article summarizes the discussions of the 3rd European Science Foundation University of Barcelona (ESF-UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain. It was focused on practical applications in routine medical practice. We provide practical recommendations for ten different clinical situations, that have either been approved or not approved by regulatory agencies. We propose some comments that might accompany the results of these tests, indicating the best drug and doses to be prescribed. The discussed examples include KRAS, cetuximab, panitumumab, EGFR gefitinib, CYP2D6-tamoxifen, TPMT azathioprine-6-mercaptopurine, VKORC1/CYP2C9 warfarin, CYP2C19-clopidogrel, HLA-B*5701-abacavir, HLA-B*5701-flucloxacillin, SLCO1B1-statins and CYP3A5-tacrolimus. We hope that these practical recommendations will help physicians, biologists, scientists and other healthcare professionals to prescribe, perform and interpret these genetic tests
AB - The present article summarizes the discussions of the 3rd European Science Foundation University of Barcelona (ESF-UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain. It was focused on practical applications in routine medical practice. We provide practical recommendations for ten different clinical situations, that have either been approved or not approved by regulatory agencies. We propose some comments that might accompany the results of these tests, indicating the best drug and doses to be prescribed. The discussed examples include KRAS, cetuximab, panitumumab, EGFR gefitinib, CYP2D6-tamoxifen, TPMT azathioprine-6-mercaptopurine, VKORC1/CYP2C9 warfarin, CYP2C19-clopidogrel, HLA-B*5701-abacavir, HLA-B*5701-flucloxacillin, SLCO1B1-statins and CYP3A5-tacrolimus. We hope that these practical recommendations will help physicians, biologists, scientists and other healthcare professionals to prescribe, perform and interpret these genetic tests
U2 - https://doi.org/10.2217/pgs.10.147
DO - https://doi.org/10.2217/pgs.10.147
M3 - Article
C2 - 21174626
SN - 1462-2416
VL - 12
SP - 113
EP - 124
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 1
ER -